\n
QUICK ANSWER: Yes. It has received two separate FDA approvals: first for type 2 diabetes management in 2022 (Mounjaro), and again for chronic weight management in adults with obesity in 2023 (Zepbound).
\n\n\n\n
Tirzepatide is a once-weekly injectable medication developed by Eli Lilly and Company that has attracted significant clinical and public attention for its performance in both type 2 diabetes management and obesity treatment. For anyone asking whether tirzepatide is FDA approved, the answer is unequivocally yes — though the specifics of those approvals, the indications they cover, and the clinical evidence that underpinned them deserve a detailed examination. Understanding the regulatory pathway a drug follows before reaching patients is not just a bureaucratic formality; it represents the accumulation of years of rigorous clinical trial data reviewed by the world’s most scrutinized pharmaceutical regulatory body.
\n\n\n\n
Table of Contents
\n\n\n\n
Why FDA Approval Status Is a Critical Research Benchmark
\n\n\n\n
FDA approval is the gold standard of pharmaceutical validation in the United States. Before any drug receives approval, the manufacturer must submit a New Drug Application (NDA) or Biologics License Application (BLA) containing comprehensive data from preclinical studies, Phase I through Phase III clinical trials, manufacturing quality assessments, and proposed labeling. Reviewers at the Center for Drug Evaluation and Research (CDER) evaluate this data against a benefit-risk framework to determine whether the evidence supports the drug’s safety and efficacy for a specific indicated population. For a novel mechanism like tirzepatide — the first approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — this process was both unprecedented in scope and historically consequential in outcome.
\n\n\n\n
Tirzepatide Brand Names: Mounjaro and Zepbound Explained
\n\n\n\n
Tirzepatide is currently marketed under two brand names in the United States, each corresponding to a distinct approved indication. Mounjaro is the brand name for tirzepatide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Zepbound is the brand name for the same molecule indicated for chronic weight management. Both products contain the identical active pharmaceutical ingredient at overlapping dose options; the separate branding reflects the different regulatory submissions, labeling requirements, and insurance coverage landscapes for the two indications. Understanding this distinction is essential when reviewing search queries like “is Mounjaro FDA approved for weight loss” or “is Zepbound the same as tirzepatide” — both of which reflect real and common public confusion.
\n\n\n\n
The Full FDA Approval Timeline
\n\n\n\n
Tirzepatide’s regulatory history unfolded in distinct phases, beginning with its Investigational New Drug (IND) application and progressing through one of the most extensive clinical development programs in the history of diabetes and obesity pharmacotherapy. The timeline below captures the key regulatory milestones that brought tirzepatide from bench to bedside.
\n\n\n\n
Key Regulatory Milestones from IND to Dual Approval
\n\n\n\n
| Date | Regulatory Event | Detail |
| 2017–2019 | Phase I / Phase II trials begin | Early dose-finding and safety studies; proof-of-concept for dual GIP/GLP-1 agonism |
| 2019–2022 | SURPASS Phase III program | Six pivotal trials across diverse type 2 diabetes populations |
| May 13, 2022 | FDA approval — Mounjaro (T2DM) | First-in-class dual GIP/GLP-1 receptor agonist approved for type 2 diabetes |
| 2021–2023 | SURMOUNT Phase III program | Four pivotal trials in adults with obesity or overweight with comorbidities |
| Nov 8, 2023 | FDA approval — Zepbound (obesity) | Approved for adults with BMI ≥30, or ≥27 with one weight-related comorbidity |
| 2024–2026 | Post-marketing studies | Ongoing MASH, heart failure, sleep apnea, and cardiovascular outcomes programs |
\n\n\n\n
Breakthrough Therapy Designation and Priority Review
\n\n\n\n
Before its formal approval, tirzepatide received Breakthrough Therapy Designation from the FDA for the treatment of type 2 diabetes. This designation is granted when preliminary clinical evidence indicates a drug may offer substantial improvement over available therapies for a serious or life-threatening condition. Breakthrough Therapy Designation facilitates more intensive FDA guidance during the development process and can accelerate the overall review timeline. The designation reflected the early Phase II data showing unusually large reductions in HbA1c and body weight compared to existing GLP-1 receptor agonists, which prompted the FDA to classify the drug as a potential step-change in the treatment of metabolic disease.[2]
\n\n\n\n
FDA Approval for Type 2 Diabetes: Mounjaro
\n\n\n\n
On May 13, 2022, the FDA approved tirzepatide under the brand name Mounjaro for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This approval represented a genuine first in pharmacological history: tirzepatide was the first approved medication to simultaneously agonize both the GIP and GLP-1 receptors — a mechanistic novelty that had been studied preclinically for years but had never before been translated into an approved therapeutic product.
\n\n\n\n
The SURPASS Clinical Trial Program Supporting Diabetes Approval
\n\n\n\n
The FDA’s approval of Mounjaro was supported by the SURPASS clinical trial program, comprising six Phase III randomized controlled trials that enrolled a diverse global population of adults with type 2 diabetes across a range of background therapies and comorbidity profiles. SURPASS-1 evaluated tirzepatide as monotherapy versus placebo. SURPASS-2 compared tirzepatide head-to-head with semaglutide 1 mg, the then-highest approved GLP-1 agonist dose for diabetes. SURPASS-3 and SURPASS-4 examined tirzepatide against basal insulin regimens. SURPASS-5 studied tirzepatide as add-on therapy to insulin glargine.[3]
\n\n\n\n
Across the SURPASS program, tirzepatide demonstrated HbA1c reductions ranging from approximately 1.87% to 2.59% at the 15 mg dose compared to baseline — reductions that exceeded those seen with both placebo and active comparators including semaglutide 1 mg, insulin degludec, and insulin glargine. In SURPASS-2, tirzepatide 10 mg and 15 mg reduced HbA1c by significantly more than semaglutide 1 mg, while simultaneously producing greater reductions in body weight.[4]
\n\n\n\n
What the Mounjaro FDA Label Covers and Excludes
\n\n\n\n
The approved label for Mounjaro specifies its use for glycemic control in type 2 diabetes and explicitly notes that it has not been studied in patients with a history of pancreatitis and that it is not indicated for the treatment of type 1 diabetes. The label also contains a boxed warning regarding the risk of thyroid C-cell tumors, a class effect observed in rodent studies for GLP-1 receptor agonists. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These warnings apply equally to both Mounjaro and Zepbound given their shared active ingredient.[5]
\n\n\n\n
FDA Approval for Obesity: Zepbound
\n\n\n\n
On November 8, 2023, the FDA approved tirzepatide under the brand name Zepbound for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition. This second approval marked a significant expansion of the tirzepatide approved uses and cemented the drug’s status as one of the most clinically impactful pharmaceutical agents introduced in the past two decades.
\n\n\n\n
The SURMOUNT Clinical Trial Program Supporting Obesity Approval
\n\n\n\n
The Zepbound approval was supported by the SURMOUNT clinical trial program. SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults without type 2 diabetes and demonstrated that tirzepatide 15 mg produced a mean body weight reduction of 20.9% over 72 weeks, compared to 3.1% in the placebo group. A total of 57% of participants receiving tirzepatide 15 mg achieved at least 20% weight reduction — a threshold previously associated almost exclusively with surgical weight loss interventions.[6]
\n\n\n\n
SURMOUNT-2 extended these findings to a population with type 2 diabetes and obesity, demonstrating mean weight reductions of up to 15.7% at the 15 mg dose. SURMOUNT-3 and SURMOUNT-4 evaluated sustained weight loss and the effects of treatment withdrawal, the latter confirming that weight regain occurred after discontinuation — consistent with the characterization of obesity as a chronic disease requiring long-term pharmacological management.[7]
\n\n\n\n
Zepbound FDA Label: Approved Population and Conditions
\n\n\n\n
The FDA label for Zepbound specifies approval for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one of the following weight-related comorbidities: hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease. Tirzepatide indications approved under Zepbound do not extend to pediatric populations, pregnancy, or individuals below the stated BMI thresholds without qualifying comorbidities.[8]
\n\n\n\n
📋 APPROVAL SUMMARY Tirzepatide holds two distinct FDA approvals: Mounjaro (May 2022) for type 2 diabetes glycemic control, and Zepbound (November 2023) for chronic weight management in qualifying adults with obesity or overweight with comorbidities.
\n\n\n\n
How Tirzepatide Works: The Dual-Agonist Science
\n\n\n\n
A significant part of the interest in tirzepatide regulatory approval stems from the novelty of its pharmacological mechanism. Unlike all prior approved GLP-1 receptor agonists — which include semaglutide, liraglutide, and others — tirzepatide is the first approved agent to simultaneously target both the GLP-1 receptor and the GIP receptor. This dual mechanism is at the heart of both its superior clinical efficacy and its status as a genuinely first-in-class drug.
\n\n\n\n
GLP-1 and GIP Receptor Agonism: What the Research Shows
\n\n\n\n
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to food ingestion. Its physiological effects include stimulation of glucose-dependent insulin secretion, suppression of glucagon release, deceleration of gastric emptying, and engagement of central nervous system pathways that promote satiety and reduce caloric intake. GIP (glucose-dependent insulinotropic polypeptide) is a related incretin secreted by intestinal K-cells that has more recently been recognized for its additional roles in lipid metabolism, adipose tissue function, and central appetite regulation. The hypothesis underlying tirzepatide’s design was that co-activating both incretin receptors would produce synergistic metabolic benefits beyond what GLP-1 agonism alone could achieve.[9]
\n\n\n\n
The “Twincretin” Concept and First-in-Class Mechanism
\n\n\n\n
Tirzepatide was engineered as a single synthetic peptide with optimized affinity for both GIP and GLP-1 receptors. Preclinical studies in rodent models of obesity and diabetes showed that dual GIP/GLP-1 agonism produced substantially greater reductions in body weight and blood glucose than GLP-1 agonism alone. Research published in Science Translational Medicine demonstrated that unimolecular dual incretins could maximize metabolic benefits across multiple species, lending early scientific credibility to tirzepatide’s development program.[10] The term “twincretin” entered the scientific literature to describe this approach, and tirzepatide became the first successfully approved representative of this mechanistic class.
\n\n\n\n
Clinical Trial Evidence Behind the Approvals
\n\n\n\n
FDA approval decisions are only as strong as the clinical evidence that supports them. For tirzepatide, that evidence base spans two separate Phase III programs — SURPASS for diabetes and SURMOUNT for obesity — comprising more than ten individual randomized controlled trials with combined enrollment of tens of thousands of participants across multiple countries and diverse demographic profiles.
\n\n\n\n
Glycemic Evidence: HbA1c Reduction Across the SURPASS Program
\n\n\n\n
Across the six SURPASS trials, tirzepatide at the 15 mg dose consistently produced HbA1c reductions of between 1.87% and 2.59% from baseline — reductions that exceeded those of all active comparators studied in the program, including semaglutide, insulin glargine, and insulin degludec. A notable feature of the glycemic data was the high proportion of participants achieving HbA1c targets below 7.0% and even below 5.7% (the threshold for normoglycemia), suggesting that tirzepatide had the potential to achieve near-normal glucose regulation in a substantial proportion of patients with long-standing diabetes.[4]
\n\n\n\n
Weight Loss Evidence: SURMOUNT-1 and the 20% Body Weight Threshold
\n\n\n\n
The weight loss evidence submitted for Zepbound was anchored by SURMOUNT-1, which remains one of the most impactful trials in the history of obesity pharmacotherapy. The 20.9% mean body weight reduction at the tirzepatide 15 mg dose over 72 weeks — in a non-diabetic population — exceeded not only any prior FDA-approved pharmacotherapy for obesity but also approached the weight loss magnitudes historically associated with sleeve gastrectomy and gastric bypass. The FDA’s review noted that this magnitude of weight loss was accompanied by clinically meaningful improvements in cardiometabolic risk factors including waist circumference, blood pressure, fasting lipids, and markers of insulin resistance.[6]
\n\n\n\n
The FDA also reviewed SURMOUNT-2 data for the Zepbound application, which demonstrated efficacy in adults with type 2 diabetes — a population in which pharmacological weight loss has historically been more difficult to achieve. The 15.7% mean weight reduction at the 15 mg dose in SURMOUNT-2 was substantially greater than any prior pharmacotherapy for obesity-with-diabetes, reinforcing the FDA’s conclusion that the weight management benefits of tirzepatide were robust across key subpopulations.[7]
\n\n\n\n
Emerging Cardiovascular and Metabolic Outcomes Evidence
\n\n\n\n
While the primary basis for both FDA approvals was glycemic control and weight reduction respectively, the totality of the evidence reviewed also included cardiometabolic secondary endpoints. Consistent improvements in systolic blood pressure (reductions of 6–10 mmHg), triglycerides, HDL cholesterol, and waist circumference were observed across both programs. A 2024 study evaluating tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH) showed significant histological improvement in liver disease.[11] Tirzepatide heart failure with preserved ejection fraction (HFpEF) data from the SUMMIT trial demonstrated significant improvement in functional capacity in obese patients with HFpEF.[12]
\n\n\n\n
FDA-Reviewed Safety Profile and Warnings
\n\n\n\n
\n\n\n\n
The FDA’s approval of any drug requires that the benefit-risk balance be favorable. For tirzepatide, the FDA’s safety review covered data from thousands of participants across both clinical programs and resulted in a labeling profile broadly consistent with the GLP-1 receptor agonist class, with some additional considerations specific to tirzepatide’s dual mechanism.
\n\n\n\n
Common Adverse Events Identified in FDA Review
\n\n\n\n
The most commonly reported adverse events in tirzepatide clinical trials were gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation. These effects are consistent with the GLP-1 receptor agonist class effect. In the SURMOUNT-1 trial, nausea was reported in approximately 31% of participants at the 15 mg dose compared to around 10% with placebo, and vomiting in approximately 20% versus 3% with placebo. Gastrointestinal adverse events were most pronounced early in the treatment period and generally diminished over time. Discontinuation due to adverse events occurred in approximately 7% of participants at the highest dose versus 2% in the placebo group.[6]
\n\n\n\n
The FDA Boxed Warning: Thyroid C-Cell Tumors and Contraindications
\n\n\n\n
Both Mounjaro and Zepbound carry the same FDA-mandated boxed warning regarding the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This warning is based on observations in rodent carcinogenicity studies in which GLP-1 receptor agonists produced thyroid C-cell adenomas and carcinomas at clinically relevant exposures. The relevance of this finding to humans has not been definitively established, and no cases of MTC directly attributable to tirzepatide have been confirmed in human clinical trials to date. Tirzepatide is contraindicated in individuals with a personal or family history of MTC or MEN 2.[5]
\n\n\n\n
Pancreatitis, Gallbladder Disease, and Vision Risk: What FDA Label Data Show
\n\n\n\n
Acute pancreatitis has been reported with GLP-1 receptor agonists as a class, and both tirzepatide labels include a precautionary statement advising discontinuation if pancreatitis is suspected. Gallbladder-related adverse events, including cholelithiasis and cholecystitis, were reported at higher rates in the tirzepatide arms of clinical trials compared to placebo — an observation that may relate to rapid weight loss and its known impact on bile composition. A 2024 study published in JAMA Ophthalmology also identified an association between semaglutide use and nonarteritic anterior ischemic optic neuropathy (NAION); while this data pertains to a related GLP-1 agent, it has prompted ongoing pharmacovigilance for tirzepatide as well.[13]
\n\n\n\n
Off-Label Research and Unapproved Indications
\n\n\n\n
FDA approval for tirzepatide currently covers two indications: type 2 diabetes and obesity or overweight with comorbidities. However, the breadth of the clinical and preclinical research program has led to active investigation of the drug’s potential in a range of conditions beyond these approved uses. Understanding what is approved versus what is under investigation is an important distinction for both researchers and clinicians.
\n\n\n\n
Tirzepatide for MASH: Regulatory Application in Progress
\n\n\n\n
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a progressive liver disease with no historically approved pharmacological treatments. A Phase III trial published in the New England Journal of Medicine in 2024 demonstrated that tirzepatide produced statistically significant histological improvement in liver fibrosis in patients with MASH, with 51% of participants in the high-dose arm achieving the primary endpoint of MASH resolution without worsening fibrosis. These findings prompted Eli Lilly to submit a regulatory application for this additional indication.[11]
\n\n\n\n
Sleep Apnea and Heart Failure Research: Expanding the Evidence Base
\n\n\n\n
The SURMOUNT-OSA trial evaluated tirzepatide in adults with obesity-related obstructive sleep apnea and demonstrated a significant reduction in the apnea-hypopnea index. The SUMMIT trial, published in 2024 in the New England Journal of Medicine, evaluated tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity, demonstrating significant improvements in functional capacity as measured by six-minute walk distance and patient-reported outcomes. These results have generated regulatory interest in additional tirzepatide label expansions, though neither indication had received formal FDA approval as of the time of publication.[12]
\n\n\n\n
📌 RESEARCH NOTE Tirzepatide is currently under investigation for MASH (liver disease), obstructive sleep apnea, heart failure with preserved ejection fraction, and polycystic ovary syndrome. These are active research areas; none represent currently approved FDA indications.
\n\n\n\n
International Regulatory Status Beyond the FDA
\n\n\n\n
While the question of whether tirzepatide is FDA approved is answered affirmatively and clearly, researchers and clinicians in other countries operate under separate regulatory frameworks with their own approval timelines and conditions. Understanding tirzepatide’s international regulatory status provides important context for the global research landscape.
\n\n\n\n
European Medicines Agency Approval: Mounjaro in the EU
\n\n\n\n
The European Medicines Agency (EMA) granted marketing authorisation for tirzepatide under the brand name Mounjaro for the treatment of type 2 diabetes in adults in September 2023. The EMA’s Committee for Medicinal Products for Human Use (CHMP) conducted its own scientific review of the SURPASS clinical program and reached conclusions broadly consistent with the FDA’s assessment — that the benefit-risk balance was favorable for glycemic management in adults with type 2 diabetes.
\n\n\n\n
MHRA Approval in the United Kingdom
\n\n\n\n
In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) granted approval for tirzepatide for type 2 diabetes, with the obesity indication subsequently approved as the SURMOUNT data were reviewed. The UK’s regulatory framework, operating independently of the EU since Brexit, conducted its own evaluation of the tirzepatide clinical package. Prescribing guidance from NICE regarding tirzepatide’s use within the National Health Service was subject to ongoing health technology assessment review as of 2025, with particular attention to cost-effectiveness thresholds that govern NHS reimbursement decisions.
\n\n\n\n
Regulatory Status in Other Major Markets
\n\n\n\n
Beyond the United States, EU, and United Kingdom, tirzepatide has received marketing approval in a growing number of countries including Japan, Australia, Canada, and several Middle Eastern and Latin American markets. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved tirzepatide for type 2 diabetes in 2023, following clinical data that included Japan-specific sub-studies within the SURPASS program addressing potential ethnic differences in pharmacokinetics and glycemic response.
\n\n\n\n
Access, Insurance, and Prescribing Landscape
\n\n\n\n
FDA approval establishes the legal and scientific foundation for a drug’s availability, but it does not by itself determine patient access. For tirzepatide, the post-approval landscape has been shaped by a complex interplay of insurance coverage decisions, manufacturer pricing, prescriber awareness, and drug supply constraints that have significantly influenced real-world access to both Mounjaro and Zepbound.
\n\n\n\n
Insurance Coverage for Tirzepatide Approved Indications
\n\n\n\n
Insurance coverage for tirzepatide varies substantially by indication and payer. Coverage for Mounjaro in the type 2 diabetes indication has generally been more straightforward to obtain, as both commercial insurance plans and Medicare have historically offered more consistent coverage of diabetes medications. Coverage for Zepbound in the obesity indication has been more variable, reflecting the longstanding reluctance of many payers to cover anti-obesity pharmacotherapy, even following FDA approval. Employer-sponsored insurance plans have shown a gradual shift toward obesity drug coverage, though premiums, formulary placement, and prior authorization requirements have created meaningful barriers for many patients.
\n\n\n\n
Drug Shortages, Compounded Tirzepatide, and FDA Enforcement
\n\n\n\n
Following FDA approval of Zepbound and the consequent surge in demand, tirzepatide experienced significant supply shortages in the United States. During shortage periods, the FDA permitted the compounding of tirzepatide by state-licensed pharmacies and outsourcing facilities under specific conditions. However, as the shortage status changed in late 2024 and 2025, the FDA issued guidance requiring that compounding of tirzepatide cease, citing concerns about product quality, variable potency, and the risk of patient harm from non-pharmaceutical-grade compounded products. This enforcement action highlighted the importance of regulatory status as a safeguard for patient safety.[14]
\n\n\n\n
Who Can Prescribe Tirzepatide and Under What Circumstances
\n\n\n\n
Tirzepatide is a prescription-only medication in the United States and all other jurisdictions where it has received regulatory approval. It may be prescribed by licensed physicians, nurse practitioners, and other qualified healthcare providers within the scope of their practice. Prescribing for the type 2 diabetes indication (Mounjaro) requires a confirmed diagnosis of type 2 diabetes mellitus. Prescribing for the obesity indication (Zepbound) requires documentation of the qualifying BMI threshold and, where applicable, the presence of at least one approved comorbid condition.[15]
\n\n\n\n
Final Thought
\n\n\n\n
The question of whether tirzepatide is FDA approved can now be answered with a level of regulatory and clinical detail that was unavailable as recently as three years ago. The drug holds two distinct and well-supported approvals — one for type 2 diabetes management and one for chronic weight management in obesity — each backed by one of the most comprehensive Phase III clinical development programs ever assembled for a metabolic disease pharmacotherapy. Its first-in-class dual GIP/GLP-1 receptor agonist mechanism has not only justified those approvals but has opened new research frontiers in MASH, sleep apnea, heart failure, and other metabolic conditions that remain under active investigation.
\n\n\n\n
What the tirzepatide regulatory story also illustrates is how rapidly the landscape of obesity and metabolic medicine can evolve when rigorous science meets genuine unmet need. For researchers, clinicians, and patients seeking evidence-grounded information about tirzepatide’s regulatory status and clinical profile, the trial record is substantial and the conclusions it supports are clear. For those interested in exploring the broader landscape of GLP-1-based peptide research, resources such as Peptides Lab UK provide access to research-grade materials and current scientific literature relevant to incretin receptor pharmacology and its expanding applications. As with all pharmacological agents, the FDA-approved labeling represents the evidence-based boundary within which clinical use is validated — a boundary that continues to expand as new data from ongoing programs reach regulatory review.
\n\n\n\n
Frequently Asked Questions
\n\n\n\n
What is tirzepatide approved for by the FDA?
\n\n\n\n
The FDA has approved tirzepatide for two indications: as Mounjaro for glycemic control in adults with type 2 diabetes (May 2022), and as Zepbound for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one comorbidity (November 2023).
\n\n\n\n
When did the FDA approve tirzepatide for weight loss?
\n\n\n\n
The FDA approved tirzepatide for weight loss on November 8, 2023, under the brand name Zepbound. This followed the earlier May 2022 diabetes approval (Mounjaro) and was supported by the SURMOUNT clinical trial program.
\n\n\n\n
Is Mounjaro the same as Zepbound?
\n\n\n\n
Yes. Both contain the identical active ingredient — tirzepatide. Mounjaro is the brand name approved for type 2 diabetes; Zepbound is the brand name approved for obesity and overweight. The separate branding reflects distinct regulatory submissions and insurance coverage pathways.
\n\n\n\n
Is tirzepatide approved for people without diabetes?
\n\n\n\n
Yes. Zepbound is approved for adults without diabetes who have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea.
\n\n\n\n
Is tirzepatide approved in the UK and Europe?
\n\n\n\n
Yes. The EMA approved tirzepatide (Mounjaro) for type 2 diabetes in September 2023. The MHRA in the UK has also approved tirzepatide. Both agencies conducted independent reviews of the SURPASS and SURMOUNT clinical data before granting approval.
\n\n\n\n
What are the FDA contraindications for tirzepatide?
\n\n\n\n
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It carries a boxed warning regarding thyroid C-cell tumor risk observed in animal studies.
\n\n\n\n
Is compounded tirzepatide legal and FDA approved?
\n\n\n\n
Compounded tirzepatide was temporarily permitted during FDA-recognized drug shortage periods. Once the shortage designation changed in 2024–2025, the FDA moved to restrict compounding, as compounded versions are not FDA-approved and carry manufacturing quality risks. Only commercially manufactured Mounjaro and Zepbound carry FDA approval.
\n\n\n\n
REFERENCES
\n\n\n\n
1. U.S. Food and Drug Administration. “New Drug Application Approval: Tirzepatide (Mounjaro).” FDA.gov. May 2022.
\n\n\n\n
2. U.S. Food and Drug Administration. “Breakthrough Therapy Designation: Tirzepatide for Type 2 Diabetes.” FDA.gov. 2020.
\n\n\n\n
3. Rosenstock J, et al. “Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1).” The Lancet. 2021;398(10295):143–155.
\n\n\n\n
4. Frías JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).” New England Journal of Medicine. 2021;385(6):503–515.
\n\n\n\n
5. U.S. Food and Drug Administration. “Mounjaro (tirzepatide) Prescribing Information.” Eli Lilly and Company. 2022.
\n\n\n\n
6. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” New England Journal of Medicine. 2022;387(3):205–216.
\n\n\n\n
7. Garvey WT, et al. “Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2).” The Lancet. 2023;402(10402):613–626.
\n\n\n\n
8. U.S. Food and Drug Administration. “Zepbound (tirzepatide) Prescribing Information.” Eli Lilly and Company. 2023.
\n\n\n\n
9. Drucker DJ. “The biology of incretin hormones.” Cell Metabolism. 2006;3(3):153–165.
\n\n\n\n
10. Finan B, et al. “Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.” Science Translational Medicine. 2013;5(209).
\n\n\n\n
11. Loomba R, et al. “Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.” New England Journal of Medicine. 2024;391(4):296–308.
\n\n\n\n
12. Nassif ME, et al. “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT).” New England Journal of Medicine. 2024;391:2051–2061.
\n\n\n\n
13. Hathaway JT, et al. “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.” JAMA Ophthalmology. 2024.
\n\n\n\n
14. U.S. Food and Drug Administration. “FDA Actions on Compounded Tirzepatide and Semaglutide.” FDA.gov. 2025.
\n\n\n\n
15. American Diabetes Association. “Standards of Care in Diabetes — 2024.” Diabetes Care. 2024;47(Suppl. 1).
\n\n
🔗 Related Reading: For a comprehensive overview of Tirzepatide research, mechanisms, UK sourcing, and safety data, see our Tirzepatide UK: Complete Research Guide (2026).
